Log in

NASDAQ:ODT - Odonate Therapeutics Stock Price, Forecast & News

$25.95
-1.71 (-6.18 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$24.52
Now: $25.95
$28.42
50-Day Range
$20.22
MA: $29.05
$34.59
52-Week Range
$16.50
Now: $25.95
$43.75
Volume38,503 shs
Average Volume99,786 shs
Market Capitalization$831.96 million
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Read More
Odonate Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ODT
CUSIPN/A
Phone858-731-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.06 per share

Profitability

Net Income$-111,820,000.00

Miscellaneous

Employees117
Market Cap$831.96 million
Next Earnings Date4/23/2020 (Estimated)
OptionableNot Optionable

Receive ODT News and Ratings via Email

Sign-up to receive the latest news and ratings for ODT and its competitors with MarketBeat's FREE daily newsletter.


Odonate Therapeutics (NASDAQ:ODT) Frequently Asked Questions

How has Odonate Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ODT shares have increased by 0.1% and is now trading at $25.95. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Odonate Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Odonate Therapeutics.

When is Odonate Therapeutics' next earnings date?

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Odonate Therapeutics.

How were Odonate Therapeutics' earnings last quarter?

Odonate Therapeutics Inc (NASDAQ:ODT) released its quarterly earnings results on Thursday, February, 20th. The company reported ($0.91) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.11. View Odonate Therapeutics' earnings history.

What price target have analysts set for ODT?

2 Wall Street analysts have issued 12-month target prices for Odonate Therapeutics' stock. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' stock price to reach $26.00 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View analysts' price targets for Odonate Therapeutics.

Has Odonate Therapeutics been receiving favorable news coverage?

Media stories about ODT stock have been trending extremely negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Odonate Therapeutics earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutOdonate Therapeutics.

Are investors shorting Odonate Therapeutics?

Odonate Therapeutics saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 815,200 shares, a decline of 20.1% from the February 27th total of 1,020,000 shares. Based on an average daily volume of 66,400 shares, the short-interest ratio is presently 12.3 days. Approximately 2.8% of the company's stock are sold short. View Odonate Therapeutics' Current Options Chain.

Who are some of Odonate Therapeutics' key competitors?

What other stocks do shareholders of Odonate Therapeutics own?

Who are Odonate Therapeutics' key executives?

Odonate Therapeutics' management team includes the following people:
  • Mr. Kevin C. Tang, Chairman & CEO (Age 52)
  • Mr. John G. Lemkey, Chief Operating Officer (Age 38)
  • Dr. Joseph P. O'Connell M.D., Chief Medical Officer (Age 65)
  • Mr. Michael S. Hearne, CFO & Principal Accounting Officer (Age 57)
  • Dr. Steven S. Pfeiffer Ph.D., VP of Technical Operations (Age 43)

When did Odonate Therapeutics IPO?

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

What is Odonate Therapeutics' stock symbol?

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Who are Odonate Therapeutics' major shareholders?

Odonate Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (4.14%), Franklin Resources Inc. (3.71%), Franklin Resources Inc. (3.71%), Driehaus Capital Management LLC (2.07%), State Street Corp (0.75%) and Pictet Asset Management Ltd. (0.61%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang. View institutional ownership trends for Odonate Therapeutics.

Which major investors are selling Odonate Therapeutics stock?

ODT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Franklin Resources Inc., Oxford Asset Management LLP, Goldman Sachs Group Inc., California Public Employees Retirement System, Chartwell Investment Partners LLC, and Spark Investment Management LLC. View insider buying and selling activity for Odonate Therapeutics.

Which major investors are buying Odonate Therapeutics stock?

ODT stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Pictet Asset Management Ltd., State Street Corp, Janus Henderson Group PLC, Virtus ETF Advisers LLC, AQR Capital Management LLC, UBS Group AG, and Bank of New York Mellon Corp. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang. View insider buying and selling activity for Odonate Therapeutics.

How do I buy shares of Odonate Therapeutics?

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Odonate Therapeutics' stock price today?

One share of ODT stock can currently be purchased for approximately $25.95.

How big of a company is Odonate Therapeutics?

Odonate Therapeutics has a market capitalization of $831.96 million. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe. View additional information about Odonate Therapeutics.

What is Odonate Therapeutics' official website?

The official website for Odonate Therapeutics is http://www.odonate.com/.

How can I contact Odonate Therapeutics?

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]


MarketBeat Community Rating for Odonate Therapeutics (NASDAQ ODT)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  144 (Thanks for Voting!)
Underperform Votes:  195 (Thanks for Voting!)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Odonate Therapeutics and other stocks. Vote "Outperform" if you believe ODT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ODT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel